This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Most Profitable Second Quarter Biotech Stocks

BOSTON ( TheStreet) -- Biotech stocks continued to march higher at a torrid pace in the first quarter, with the Nasdaq Biotechnology Index (NBI) up 15% compared to a 10% rise in the S&P 500. In fact, the NBI is now comfortably at an all-time high, even higher today that it was during the crazy dot-com and genomics bubble of 1999-2000.

The best way for investors to profit from biotech trading is by staying on top of the most important stock-moving events. To make this job easier, I compiled a list of the most significant biotech trading catalysts for the second quarter. Happy trading!

Sarepta Therapeutics (SRPT - Get Report): Decision on the accelerated approval filing for eteplirsen to treat patients with Duchenne Muscular Dystrophy (exon 51.) Sarepta met with FDA late last month to discuss the eteplirsen filing, so expect a public announcement towards the end of April.

Zogenix (ZGNX - Get Report): FDA approval decision for Zohydro, an extended-release formulation of the chronic pain drug hydrocodone without acetaminophen. A decision could come at any time following a delay of the original March 1 PDUFA date.

Arena Pharmaceuticals (ARNA - Get Report): The U.S. commercial launch of the weight-loss pill Belviq in April plus a possible approval decision by European regulators.

Delcath Systems (DCTH): FDA advisory panel reviewing Melblez on May 2. The FDA approval decision is expected on June 14.

Aveo Pharmaceuticals (AVEO): FDA advisory panel reviewing Tivozanib also on May 2.

Vivus (VVUS): FDA decision expected in April on loosening marketing restrictions on the weight-loss pill Qsymia, including allowing the drug to be sold in retail pharmacies.

Titan Pharmaceuticals (TTNP): FDA approval decision for Probuphine on April 30. Don't be surprised if the decision is delayed three months because Titan and FDA are still working on a final risk management plan.

Hepatitis C drug stocks: The European Association for the Study of Liver Disease (EASL) will release research abstracts for its closely spring meeting on April 8. The actual EASL meeting is held April 24-28. Investor focus will be on new and updated data from Gilead Sciences (GILD - Get Report), Achillion Pharmaceuticals (ACHN), Bristol-Myers Squibb (BMY), Merck (MRK), Abbvie (ABBV) and others.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ZGNX $1.39 -0.71%
ARNA $4.19 -0.48%
GILD $102.82 -0.17%
INFI $12.10 -4.00%
SRPT $14.44 9.00%

Markets

DOW 17,885.96 -42.24 -0.24%
S&P 500 2,084.49 -4.97 -0.24%
NASDAQ 4,928.3960 -10.9310 -0.22%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs